Dai Nan-Nan, Hu Man-Yi, Wang Jian-Ping, Dai Zhi-Hui, Xu Li, Ye Tai-Wei
Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, Zhejiang Province, China.
Cancer Immunol Immunother. 2025 Jun 21;74(8):245. doi: 10.1007/s00262-025-04108-x.
Immunotherapy has shown limited efficacy in colorectal cancer (CRC), necessitating the urgent identification of novel immunotherapeutic targets to address this challenge. Tertiary lymphoid structures (TLSs) are complex immune structures that spontaneously form within and outside of the tumor microenvironment, resembling secondary lymphoid organs. The formation of TLS formation dynamically adapts to the tumor microenvironment, with their immune function maintained by resident immune cells and cytokine networks. TLS develops antitumor immune competence following dynamic reorganization of their cellular components and proportions, although the precise mechanistic underpinnings remain to be fully characterized. Numerous studies have demonstrated that TLS can modulate the immune status of CRC, potentially enhancing the efficacy of immunotherapy. Currently, the clinical setting lacks appropriate immunological markers to assess immunotherapy outcomes, and TLS may offer a solution to this limitation. This article will review current research on TLS as a novel therapeutic target in the immunotherapy of malignant colorectal tumors.
免疫疗法在结直肠癌(CRC)中的疗效有限,因此迫切需要确定新的免疫治疗靶点来应对这一挑战。三级淋巴结构(TLSs)是在肿瘤微环境内外自发形成的复杂免疫结构,类似于二级淋巴器官。TLS的形成动态适应肿瘤微环境,其免疫功能由驻留免疫细胞和细胞因子网络维持。TLS在其细胞成分和比例发生动态重组后发展出抗肿瘤免疫能力,尽管其确切的机制基础仍有待充分阐明。大量研究表明,TLS可以调节CRC的免疫状态,有可能提高免疫治疗的疗效。目前,临床环境缺乏评估免疫治疗结果的合适免疫标志物,而TLS可能为解决这一局限性提供方案。本文将综述目前关于TLS作为恶性结直肠肿瘤免疫治疗新靶点的研究。